Pat Soon-Shiong, Executive Chairman at ImmunityBio, shared on X:
“Proud moment for our team and for patients across Europe. Our first EU (German) labeling and packaging run for ANKTIVA is complete.
These vials represent more than manufacturing. They mark the next step in bringing this IL-15 immunotherapy to patients with BCG-unresponsive NMIBC who previously faced limited options. Global access continues. Unstoppable.”
Other articles featuring Pat Soon-Shiong on OncoDaily.